TY - JOUR T1 - Long-COVID in Children and Adolescents: A Systematic Review and Meta-analyses JF - medRxiv DO - 10.1101/2022.03.10.22272237 SP - 2022.03.10.22272237 AU - Sandra Lopez-Leon AU - Talia Wegman-Ostrosky AU - Norma Cipatli Ayuzo del Valle AU - Carol Perelman AU - Rosalinda Sepulveda AU - Paulina A Rebolledo AU - Angelica Cuapio AU - Sonia Villapol Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/06/06/2022.03.10.22272237.abstract N2 - The objective of this systematic review and meta-analyses is to estimate the prevalence of long-COVID in children and adolescents and to present the full spectrum of symptoms present after acute COVID-19. We have used PubMed and Embase to identify observational studies published before February 10th, 2022 that included a minimum of 30 patients with ages ranging from 0 to 18 years that met the National Institute for Healthcare Excellence (NICE) definition of long-COVID, which consists of both ongoing (4 to 12 weeks) and post-COVID-19 (≥12 weeks) symptoms. Random-effects meta-analyses were performed using the MetaXL software to estimate the pooled prevalence with a 95% confidence interval (CI). Heterogeneity was assessed using I2 statistics. The Preferred Reporting Items for Systematic Reviewers and Meta-analysis (PRISMA) reporting guideline was followed (registration PROSPERO CRD42021275408). The literature search yielded 8,373 publications, of which 21 studies met the inclusion criteria, and a total of 80,071 children and adolescents were included. The prevalence of long-COVID was 25.24%, and the most prevalent clinical manifestations were mood symptoms (16.50%), fatigue (9.66%), and sleep disorders (8.42%). Children infected by SARS-CoV-2 had a higher risk of persistent dyspnea, anosmia/ageusia, and/or fever compared to controls. Limitations of the studies analyzed include lack of standardized definitions, recall, selection, misclassification, nonresponse and/or loss of follow-up, and a high level of heterogeneity.Competing Interest StatementSLL is an employee of Novartis Pharmaceutical Company; the statements presented in the paper do not necessarily represent the position of the company. The remaining authors have no competing interests to declareFunding StatementThis work was supported by funds from Houston Methodist Research Institute, Houston, TX.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data relevant to the study are included in the article or uploaded as supplementary information. In addition, the datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.CICredible intervalCOVID-19Coronavirus disease 2019CSScross-sectional studyDMdiabetes mellitusQCedQuality-ControlledIRRIncidence Rate RatiosNICENational Institute for Health and Care ExcellenceMIS-Cmultisystem inflammatory syndromeORsOdds RatiosPCSprospective cohort studyPRISMAPreferred Items for Systematic Reviews and Meta-AnalysesRCSretrospective cohort studyrt-PCRreal-time reverse transcription-polymerase chain reactionSARS-CoV-2severe acute respiratory syndrome coronavirus 2PASCpost-acute sequelae of SARS-CoV-2 ER -